1. Corrigendum to "HEART UK consensus statement on Lipoprotein(a): A call to action" [Atherosclerosis 291 (2019) 62–70]. (March 2020) Authors: Cegla, Jaimini; Neely, R. Dermot G.; France, Michael; Ferns, Gordon; Byrne, Chris D.; Halcox, Julian; Datta, Dev; Capps, Nigel; Shoulders, Carol; Qureshi, Nadeem; Rees, Alan; Main, Linda; Cramb, Robert; Viljoen, Adie; Payne, Jules; Soran, Handrean Journal: Atherosclerosis Issue: Volume 296(2020) Page Start: 48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?. (May 2022) Authors: Catapano, Alberico L.; Daccord, Magdalena; Damato, Elaine; Humphries, Steve E.; Neely, R. Dermot G.; Nordestgaard, Børge G.; Pistollato, Michele; Steinhagen-Thiessen, Elisabeth Journal: Atherosclerosis Issue: Volume 349(2022) Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Omega‐3 fatty acids and/or fluvastatin in hepatitis C prior non‐responders to combination antiviral therapy – a pilot randomised clinical trial. (14th October 2013) Authors: Sheridan, David A.; Bridge, Simon H.; Crossey, Mary M. E.; Felmlee, Daniel J.; Fenwick, Fiona I.; Thomas, Howard C.; Neely, R. Dermot G.; Taylor‐Robinson, Simon D.; Bassendine, Margaret F. Journal: Liver international Issue: Volume 34:Number 5(2014:Jun.) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗